CN102688407B - Chinese medicinal composition for treating chronic heart failure - Google Patents
Chinese medicinal composition for treating chronic heart failure Download PDFInfo
- Publication number
- CN102688407B CN102688407B CN201210197892XA CN201210197892A CN102688407B CN 102688407 B CN102688407 B CN 102688407B CN 201210197892X A CN201210197892X A CN 201210197892XA CN 201210197892 A CN201210197892 A CN 201210197892A CN 102688407 B CN102688407 B CN 102688407B
- Authority
- CN
- China
- Prior art keywords
- parts
- medicinal composition
- heart failure
- chinese medicinal
- rhizoma alismatis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a Chinese medicinal composition for treating chronic heart failure, and belongs to the technical field of medicines. The Chinese medicinal composition comprises the following raw materials in parts by weight: 10 to 15 parts of radix pseudostellariae, 10 to 20 parts of rhizoma alismatis, 10 to 15 parts of astragalus mongholicus, 10 to 20 parts of red-rooted salvia root, 20 to 30 parts of corn stigma, and 5 to 10 parts of cassia twig. The Chinese medicinal composition can be used for remarkably solving the problem of cardiac edema of a patient with slow heart failure diuretic resistance, can be used for improving heart functions, relieving patient symptoms, improving living quality of the patient and prolonging surviving time while playing the effect of diuresis, and has small influence to blood electrolyte. The medicinal composition has the advantages of easily available raw materials, easy preparation method, exact curative effect in animal experiments and clinical tests and no toxic or side effect to human bodies currently.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition of chronic heart failure, belong to medical technical field.
Background technology
The patient is often with retention of sodium and water in chronic heart failure (chronic heart failure, CHF), and diuretic plays pivotal role in the treatment of CHF, and most of patients can be improved the CHF symptom effectively by diuretic therapy.But along with PD, some patients were is in the situation that enough application diuretic therapies, and cardiac edema can not get effective control, diuretic opposing phenomenon appears, lack at present effective treatment means.
Summary of the invention
The object of the present invention is to provide a kind of effectively Chinese medicine composition of chronic heart failure.
The raw material of described Chinese medicine composition is comprised of the component of following parts by weight:
Radix Pseudostellariae 10-15 part, Rhizoma Alismatis 10-20 part, Radix Astragali 10-15 part, Radix Salviae Miltiorrhizae 10-20 part, Stigma Maydis 20-30 part, Ramulus Cinnamomi 5-10 part.
Described Radix Pseudostellariae is Zherong, Fujian Radix Pseudostellariae, and Rhizoma Alismatis is Rhizoma Alismatis.
The preparation method of this Chinese medicine composition is as follows: get Chinese medicine according to aforementioned proportion, use distilled water immersion 1-3h, then decoct 2-3 time, each 1-2 hour, collecting decoction.Filter, filtrate is concentrated into sticky shape (T=60 ℃), packing.
The raw material of Chinese medicine that the present invention adopts, its main effect is as follows:
The dried root that Radix Pseudostellariae is Caryophyllaceae Pseudostellaria Pax plant Radix Ginseng Pseudostella ria heterop hy lla (M iq.) Pax ex Pax et Hoffm.Sweet in the mouth, micro-hardship, tepor, have the supplementing QI for promoting the production of body fluid effect.Modern pharmacology finds that Radix Pseudostellariae is containing various trace elements, aminoacid, saccharide, glycoside, phospholipid and cyclic peptide etc.For cardiopalmus, palpitation with a distress feeling, edema, anti-tired, anti-stress.There is the effects such as slow down aging, enhancing immunity and antioxidation.Can reduce IL-6 in serum, TNF-α and iNOS level, suppress the activity of substrate gold fibroin enzyme, improve myocardial remodelling and improve cardiac function, heart failure is had to protective effect.
The tuber that Rhizoma Alismatis is the perennial limnocryptophyte Rhizoma Alismatis of Alismataceae Alisma P1antago aquaticaL.Var.orientale Sam.This product is cold in nature, slightly sweet flavor, cold can heat clearing away, sweet light eliminating dampness by diuresis, enter kidney and bladder, can let out fire mutually, except damp-heat in the urinary bladder, the product that expel the heat-evil for diuretic, for the edema of retention of water-damp, the cards such as the leukorrhagia stranguria with turbid discharge of dysuria and damp invasion of lower energizer.Contain higher Alisol B monoacetate in Rhizoma Alismatis, this composition has diuresis, improves the effect of lipid metabolism.
The dry root that the Radix Astragali (Radix Astragali) is leguminous plant Radix Astragali Astragalus membranaceus (Fisch.) Bge..Slightly warm in nature, sweet in the mouth, have the merit of QI invigorating, inducing diuresis to remove edema etc.Modern pharmacological research finds that the Radix Astragali can suppress myocardial cell phosphodiesterase and Na
+-K
+-atpase activity, reduce AMP and decompose, and increases flow of calcium ions, strengthens myocardial contraction and cardiotonic; Can partly suppress the secretion of feritin, Angiotensin II, the expansion blood vessel, improve Peripheral resistance, lightening heart load; Raise Cytoplasm mitochondrion and glycogen granule, improve myocardial cell energy metabolism and anoxia tolerance function, improve remodeling ventricle.
The dry root and rhizome that Radix Salviae Miltiorrhizae is dicotyledon Labiatae Labiatae salvia Radix Salviae Miltiorrhizae Salvia miltiorrhiza Bge..Bitter in the mouth, be slightly cold.GUIXIN, Liver Channel.Promoting blood flow to regulate menstruation is arranged, stasis-dispelling and pain-killing, removing heat from blood eliminating carbuncle, the relieving restlessness that clears away heart-fire, the effect of nourishing blood to tranquillize the mind.Its effective ingredient is TANSHINONES and danshensu, and the energy anticoagulant, improve high blood coagulation state and Myocardial Microcirculation, and blood vessel dilating, improve the effects such as lipid metabolism.
Stigma Maydis (stigma maydis) is the style of grass Semen Maydis ZeamaysL..The property flat, sweet in the mouth, inducing diuresis to remove edema is arranged, the effect of liver heat removing function of gallbladder promoting.The Multiple components such as fatty oil, saponin, bitterness glucosides, alkaloid, flavonoid, potassium nitrate, vitamin K3, ascorbic acid, organic acid, have the effects such as diuresis, blood pressure lowering, blood sugar lowering, adjusting immunity, antioxidant radical.
The dry twig that Ramulus Cinnamomi is Lauraceae aiphyllium plant Cortex Cinnamomi (Cinnamomum cassia Presl).Acrid, sweet, warm.GUIXIN, lung, urinary bladder channel.The effect of dispersing cold for relieving pain, promoting the flow of QI-blood by warming the meridian, supporing yang activating QI, the flat gas that spins.Modern pharmacological research finds that its main component is cinnamic aldehyde, benzyl benzoate, cinnamyl acetate, β-cadinene, Chang Pu alkene, coumarin.There is heart tonifying, improve microcirculation, antiinflammatory, anti-platelet aggregation.Suppress Endothelin, the secretion of feritin and Angiotensin II, improve Atrial Natriuretic Factor.
The present invention can significantly improve slow heart failure diuretic opposing patient's cardiac edema problem, and this medicine, in diuresis, can improve cardiac function, patients in remission, improves patients ' life quality, extends life span, less on the electrolyte balance impact.
This drug regimen raw material is easy to get, and preparation method is easy, cell experiment, zoopery and clinical trial determined curative effect, has not yet to see the human body toxic side effect.
The specific embodiment
Embodiment 1 most preferred embodiment
Chinese medicine composition of the present invention is comprised of following:
Radix Pseudostellariae 15g, Rhizoma Alismatis 20 g, the Radix Astragali 15 g, Radix Salviae Miltiorrhizae 20 g, Stigma Maydis 30 g, Ramulus Cinnamomi 10 g purchased from the Zherong, Fujian.
The preparation method of Chinese medicine composition is as follows: gets Chinese medicine according to aforementioned proportion, with the distilled water immersion 3h of 10 times of volumes, then decocts 3 times, and each 2 hours, collecting decoction.Filter, filtrate is concentrated into sticky shape (T=60 ℃), and concentrate is placed in to water-bath (T=60 ℃) evaporation, is dried to powder, adds right amount of auxiliary materials, makes capsule.Every 0.4g(is equivalent to crude drug 3g), hereinafter to be referred as the edema with the heart involved open capsule.
Embodiment 2
The raw material of Chinese medicine composition of the present invention is comprised of the component of following weight ratio:
Radix Pseudostellariae 10 g, Rhizoma Alismatis 10 g, the Radix Astragali 10 g, Radix Salviae Miltiorrhizae 10 g, Stigma Maydis 20 g, Ramulus Cinnamomi 5 g.
Described Radix Pseudostellariae is Zherong, Fujian Radix Pseudostellariae, and Rhizoma Alismatis is Rhizoma Alismatis.
The preparation method of this Chinese medicine composition is as follows: gets Chinese medicine according to aforementioned proportion, uses distilled water immersion 1h, then decoct 2 times, and each 1 hour, collecting decoction.Filter, filtrate is concentrated into sticky shape (T=60 ℃), packing.
Embodiment 3
The raw material of Chinese medicine composition of the present invention is comprised of the component of following weight ratio:
Radix Pseudostellariae 13 g, Rhizoma Alismatis 12 g, the Radix Astragali 13 g, Radix Salviae Miltiorrhizae 15 g, Stigma Maydis 25 g, Ramulus Cinnamomi 8 g.
Described Radix Pseudostellariae is Zherong, Fujian Radix Pseudostellariae, and Rhizoma Alismatis is Rhizoma Alismatis.
The preparation method of this Chinese medicine composition is as follows: get Chinese medicine according to aforementioned proportion, use distilled water immersion 1-3h, then decoct 2-3 time, each 1-2 hour, collecting decoction.Filter, filtrate is concentrated into sticky shape (T=60 ℃), packing.
Application Example: the concrete medical usage of medicine of the present invention, pharmacological action, effective dose and using method.
1) concrete medical usage: for the patient of Patients with Chronic Heart Failure or the opposing of chronic heart failure companion diuretic;
2) pharmacological action: by acting on the neuroendocrine factor that chronic heart failure is relevant (vassopressin, feritin, angiotensin and aldosterone etc.), play diuresis, blood vessel dilating, lightening heart load, delay Myocardial Remodeling, improves cardiac function;
3) effective dose and using method: each 3 (every 0.4g), every day 3 times, ante cibum is oral;
4) technique effect:
The experiment of hypoxia in vitro/reoxygenation is found, the myocardial cell that edema with the heart involved open capsule water extract is intervened, and anti-the being subject to property of anoxia is than the obvious enhancing of matched group.The mRNA of the reticent aquaporin-1 of siRNA, its pathomorphism of cell that the edema with the heart involved open capsule is intervened is similar to matched group.Therefore, we propose, and the edema with the heart involved open capsule may improve the metabolism of myocardial cell water liquid by aquaporin-1.
In the myocardial ischemia-reperfusion rat, find, the edema with the heart involved open capsule can dwindle ischemic region, obviously improves cardiac muscular tissue's edema, and myocardial ischemia reperfusion injury suppresses Endothelin, and the secretion of feritin and Angiotensin II improves Atrial Natriuretic Factor.With matched group relatively, the rat of edema with the heart involved open capsule group, cardiac function be improved significantly.Find in addition, the edema with the heart involved open capsule is by aquaporin-1(aquaporin-1 in the upper centring myocyte), strengthen the inside and outside water liquid exchange of cell, thereby improve the water liquid metabolism of cell.
74 routine CHF companion diuretic opposing patients, be divided into edema with the heart involved open capsule treatment group 38 examples and conventional western medicine matched group 34 examples (medicine that conventional Western medicine is used has: angiotensin-convertion enzyme inhibitor (ACEI), beta-blocker, dobutamine, cedilanid, furosemide, hydrogen chlorine plug piperazine, spironolactone, nitroglycerin, sodium nitroprusside etc.) at random.Each 3 of the oral edema with the heart involved open capsule for the treatment of group, every day 3 times, 7 days be a course for the treatment of, observes altogether two courses for the treatment of.Respectively at the 7th day and the 14th day, observe two groups day urine amount, cardiac functional grading, Left Ventricular Ejection Fraction, serum electrolyte, hepatic and renal function, and the situation of change of the indexs such as dyspnea, body weight, heart rate and blood pressure.The result demonstration, the obvious effective rate of urine amount, dyspnea and the cardiac function of first course of therapy group is respectively 61%, 33% and 36%, and effective percentage is respectively 92%, 78% and 58%, and inefficiency is 8%, 26% and 30%; The obvious effective rate of matched group is respectively 28%, 19% and 17%, effective percentage 58%, 78% and 69%, and inefficiency is 42%, 22% and 31% (P<0.05).Second the course for the treatment of above-mentioned each index treatment group obvious effective rate be respectively 71%, 47% and 47%, effective percentage is 97%, 82% and 82%, inefficiency is 3%, 18% and 18%; The obvious effective rate of second course for the treatment of of matched group is respectively 33%, 42% and 39%, and effective percentage is 64%, 83% and 75%, and inefficiency is 36%, 17% and 25%.Comprehensive two the measuring index discoveries course for the treatment of, the obvious effective rate of the first course of therapy group day urine amount, dyspnea and body weight, and the effective percentage of day urine amount and inefficiency and matched group comparison, have significant difference (P<0.05).There were significant differences (P<0.05) than matched group for obvious effective rate, effective percentage and the inefficiency of day urine amount of the second course of therapy group.The diuretic for the treatment of group and other Western medicine amount ratio matched groups obviously reduce, and the some patients were diuretic of having stopped using, and curative effect remains better.The edema with the heart involved open capsule, in effective diuresis, can obviously improve Left Ventricular Ejection Fraction, heart rate and body weight (P<0.05), and hepatic and renal function and blood water power medium are not found to harmful effect, untoward reaction also do not occur.Follow up a case by regular visits to some patients were and find, this capsule of long-term taking, some patients were is all stopped using diuretic, and cardiac function also has better improvement, and curative effect maintains better, reduces admission rate again, and patient compliance is good, and routine dose has no untoward reaction.
5) the toxicology test data of medicine.
Have no toxic and side effects in cell, animal and clinical experiment.
It is below several case of the present invention.
Case 1:
Zhang, the man, 67 years old, the Yongzhou City, Hunan Province people, chronic heart failure more than 10 years, heart rate 95 times/minutes, blood pressure 135/72mmHg, cardiac function NYHA Ш level, dyspnea, left cardiac ejection fraction 35%, 24h urine amount is about 550ml, hydrosarca, body weight 80.7kg.Before treatment, 24h furosemide consumption 1200mg and spironolactone consumption are 120mg, blood urea nitrogen 21.8mmol/l, and the blood electrolyte disorder, often appear in serum creatinine 385.6mmol/l.During first course for the treatment of of oral edema with the heart involved open capsule, heart rate 80 times/minutes, cardiac function is improved as the II level, left cardiac ejection fraction 50%, body weight is 71kg, a day urine amount is about 1500ml, blood pressure 130/70 mmHg, dyspnea and edema are obviously improved.No longer application after first end course for the treatment of of furosemide and spironolactone.Follow up a case by regular visits to second course for the treatment of, These parameters is further improved, and the edema with the heart involved open capsule coordinates ACEI(captopril 25mg, every day 3 times) and beta-blocker (metoprolol 12.5mg, every day 2 times) treatment, curative effect is effectively consolidated, and patients ' life quality is greatly improved.
Case 2:
Lee, the female, 71 years old, Shantou, Guangdong people from city, chronic heart failure more than 20 years, heart rate 85 times/minutes, blood pressure 145/85mmHg, cardiac function NYHA Ш level, dyspnea, left cardiac ejection fraction 37%, 24h urine amount is about 620ml, hydrosarca, body weight 78.6kg.Before treatment, 24h furosemide consumption 1600mg and spironolactone consumption are 180mg, blood urea nitrogen 27.7mmol/l, and serum creatinine 458.7mmol/l, blood electrolyte often gets muddled.During first course for the treatment of of oral edema with the heart involved open capsule, heart rate 70 times/minutes, cardiac function is improved as the II level, left cardiac ejection fraction 48%, body weight is 70kg, a day urine amount is about 1440ml, blood pressure 135/72 mmHg, dyspnea and edema are obviously improved.When furosemide and spironolactone finish first course for the treatment of, consumption is respectively 80mg and 40mg.Follow up a case by regular visits to second course for the treatment of, These parameters is further improved, and diuretic is no longer application.The edema with the heart involved open capsule coordinates ACEI(captopril 12.5mg, every day 3 times), beta-blocker (metoprolol 12.5mg, every day 2 times) and digoxin (0.125mg, treatment once a day), curative effect is effectively consolidated, and patients ' life quality also is greatly improved.
Claims (1)
1. the Chinese medicine composition of a chronic heart failure, it is characterized in that: the raw material of described Chinese medicine composition is comprised of the component of following parts by weight: Radix Pseudostellariae 10-15 part, Rhizoma Alismatis 10-20 part, Radix Astragali 10-15 part, Radix Salviae Miltiorrhizae 10-20 part, Stigma Maydis 20-30 part, Ramulus Cinnamomi 5-10 part; Described Radix Pseudostellariae is Zherong, Fujian Radix Pseudostellariae, and Rhizoma Alismatis is Rhizoma Alismatis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210197892XA CN102688407B (en) | 2012-06-15 | 2012-06-15 | Chinese medicinal composition for treating chronic heart failure |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210197892XA CN102688407B (en) | 2012-06-15 | 2012-06-15 | Chinese medicinal composition for treating chronic heart failure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102688407A CN102688407A (en) | 2012-09-26 |
| CN102688407B true CN102688407B (en) | 2013-12-04 |
Family
ID=46854251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210197892XA Expired - Fee Related CN102688407B (en) | 2012-06-15 | 2012-06-15 | Chinese medicinal composition for treating chronic heart failure |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102688407B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102961491A (en) * | 2012-10-26 | 2013-03-13 | 郗光敏 | Traditional Chinese medicine composition for treating chronic congestive heart failure |
| CN111991500A (en) * | 2020-09-29 | 2020-11-27 | 江西中医药大学 | Traditional Chinese medicine incense for relieving chronic heart failure and preparation process thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102145089A (en) * | 2011-03-31 | 2011-08-10 | 新疆医科大学附属中医医院 | Traditional Chinese medicine for treating heart failure |
-
2012
- 2012-06-15 CN CN201210197892XA patent/CN102688407B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102145089A (en) * | 2011-03-31 | 2011-08-10 | 新疆医科大学附属中医医院 | Traditional Chinese medicine for treating heart failure |
Non-Patent Citations (1)
| Title |
|---|
| 彭敬师.慢性心力衰竭的中西医结合治疗.《中国社区医师（综合版）》.2005,第7卷(第20期),第56页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102688407A (en) | 2012-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103690783B (en) | Chinese medicine preparation being used for the treatment of diabetes and preparation method thereof | |
| CN102772748B (en) | Traditional Chinese medicine preparation for treating liver-depression qi-stagnation type viral myocarditis and preparation method thereof | |
| CN101524469B (en) | Chinese herbal medicine compound preparation for treating congestive heart failure and preparation method thereof | |
| CN101502588B (en) | Composition for beauty treatment and removing blain and method for preparing the same | |
| CN103520572A (en) | Traditional Chinese composition used for treating atopic dermatitis as well as preparation method of composition | |
| CN102526498B (en) | Chinese medicine for eliminating toxic and side effects after nasopharyngeal carcinoma radiotherapy and preparation method and administration way thereof | |
| CN104998129A (en) | Traditional Chinese medicine preparation for subarachnoid hemorrhage and preparation method thereof | |
| CN103083607B (en) | Traditional Chinese medicine composition for treating chronic renal insufficiency | |
| CN102688407B (en) | Chinese medicinal composition for treating chronic heart failure | |
| CN103006989B (en) | Medical composition for treating diabetic nephropathy | |
| CN102526676B (en) | Traditional Chinese medicine for treating chronic heart failure, preparation method and administration mode | |
| CN103463409A (en) | Traditional Chinese medicine formula for treating heart qi deficiency | |
| CN103272105B (en) | Tablet for treating diabetic nephropathy | |
| CN106668431B (en) | A Chinese medicinal composition with effects of warming kidney and invigorating qi, and its preparation method and application | |
| CN104027433B (en) | A kind of Chinese medicine composition and preparation method thereof and clinical preparation | |
| CN104248742A (en) | Traditional Chinese medicinal composition for treating cancers, and preparation method thereof | |
| CN105250588A (en) | Chinese herbal preparation for treating kidney failure and preparation method of Chinese herbal preparation | |
| CN101912460B (en) | Preparation method for improving ginsenoside-containing Chinese medicinal extract quality | |
| CN104324185A (en) | Traditional Chinese medicine composition for treating leukorrhagia and preparation method thereof | |
| CN104127670A (en) | Traditional Chinese medicine decoction for treating arrhythmia | |
| CN103099204A (en) | Dried rehamnnia root health care composition and preparation technology thereof | |
| CN103690834B (en) | A kind of blood pressure lowering Chinese medicinal composition and preparation method thereof | |
| CN101322788B (en) | Chinese medicine for treating vitiligo and preparation | |
| CN101129489A (en) | Compound kidney reinforcing patch | |
| CN1432393A (en) | Chinese medicine prepn for treating coronary heart disease and angina pectoris and its prepn |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131204 Termination date: 20170615 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |